Cargando…

α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism

BACKGROUND: Mutations in glucocerebrosidase (GBA) cause Gaucher disease (GD) and increase the risk of developing Parkinson’s disease (PD) and Dementia with Lewy Bodies (DLB). Since both genetic and environmental factors contribute to the pathogenesis of sporadic PD, we investigated the susceptibilit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yun, Seung Pil, Kim, Donghoon, Kim, Sangjune, Kim, SangMin, Karuppagounder, Senthilkumar S., Kwon, Seung-Hwan, Lee, Saebom, Kam, Tae-In, Lee, Suhyun, Ham, Sangwoo, Park, Jae Hong, Dawson, Valina L., Dawson, Ted M., Lee, Yunjong, Ko, Han Seok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759291/ https://www.ncbi.nlm.nih.gov/pubmed/29310663 http://dx.doi.org/10.1186/s13024-017-0233-5

Ejemplares similares

D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model
por: Kim, Donghoon, et al.
Publicado: (2018)

Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation
por: Galvagnion, Céline, et al.
Publicado: (2022)

Linking Gba1 E326K mutation to microglia activation and mild age-dependent dopaminergic Neurodegeneration
por: Kweon, Sin Ho, et al.
Publicado: (2023)

The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice
por: Migdalska-Richards, Anna, et al.
Publicado: (2017)

L444P Gba1 mutation increases formation and spread of α-synuclein deposits in mice injected with mouse α-synuclein pre-formed fibrils
por: Migdalska‐Richards, Anna, et al.
Publicado: (2020)

Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations
por: Li, Hongyu, et al.
Publicado: (2018)

The SPID-GBA study: Sex distribution, Penetrance, Incidence, and Dementia in GBA-PD
por: Straniero, Letizia, et al.
Publicado: (2020)

The Consequences of GBA Deficiency in the Autophagy–Lysosome System in Parkinson’s Disease Associated with GBA
por: Pradas, Eddie, et al.
Publicado: (2023)

Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review
por: Behl, Tapan, et al.
Publicado: (2021)

POLG R964C and GBA L444P mutations in familial Parkinson's disease: Case report and literature review
por: Hsieh, Pei‐Chen, et al.
Publicado: (2019)

GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds
por: Brockmann, Kathrin
Publicado: (2020)

The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease
por: Karuppagounder, Senthilkumar S., et al.
Publicado: (2014)

c-Abl and Parkinson’s Disease: Mechanisms and Therapeutic Potential
por: Brahmachari, Saurav, et al.
Publicado: (2017)

Resistance to MPTP-Neurotoxicity in α-Synuclein Knockout Mice Is Complemented by Human α-Synuclein and Associated with Increased β-Synuclein and Akt Activation
por: Thomas, Bobby, et al.
Publicado: (2011)

The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models
por: Polinski, Nicole K., et al.
Publicado: (2022)

The Role of Cholesterol in α‐Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease
por: García‐Sanz, Patricia, et al.
Publicado: (2020)

Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
por: Yun, Seung Pil, et al.
Publicado: (2018)

Correction: Resistance to MPTP-Neurotoxicity in α-Synuclein Knockout Mice Is Complemented by Human α-Synuclein and Associated with Increased β-Synuclein and Akt Activation
por: Thomas, Bobby, et al.
Publicado: (2012)

Cell-Based Screen Using Amyloid Mimic β23 Expression Identifies Peucedanocoumarin III as a Novel Inhibitor of α-Synuclein and Huntingtin Aggregates
por: Ham, Sangwoo, et al.
Publicado: (2019)

Glucocerebrosidase Mutations and Synucleinopathies. Potential Role of Sterylglucosides and Relevance of Studying Both GBA1 and GBA2 Genes
por: Franco, Rafael, et al.
Publicado: (2018)

Overexpression of Parkinson’s Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology
por: Xiong, Yulan, et al.
Publicado: (2017)

Comparative Transcriptome Analysis in Monocyte-Derived Macrophages of Asymptomatic GBA Mutation Carriers and Patients with GBA-Associated Parkinson’s Disease
por: Usenko, Tatiana, et al.
Publicado: (2021)

Impact of Gba2 on neuronopathic Gaucher’s disease and α-synuclein accumulation in medaka (Oryzias latipes)
por: Nakanishi, Etsuro, et al.
Publicado: (2021)

Dual-Task Performance in GBA Parkinson's Disease
por: Srulijes, Karin, et al.
Publicado: (2017)

GBA Variants and Parkinson Disease: Mechanisms and Treatments
por: Smith, Laura, et al.
Publicado: (2022)

Is Gauchian genotyping of GBA1 variants reliable?
por: Tayebi, Nahid, et al.
Publicado: (2023)

No evidence for substrate accumulation in Parkinson brains with GBA mutations
por: Gegg, Matthew E., et al.
Publicado: (2015)

The Enigmatic Role of GBA2 in Controlling Locomotor Function
por: Woeste, Marina A., et al.
Publicado: (2017)

Cognitive Functioning of Glucocerebrosidase (GBA) Non-manifesting Carriers
por: Moran, Eileen E., et al.
Publicado: (2021)

Dancing Feet Dyskinesia in a Patient with GBA-PD
por: Olszewska, Diana A., et al.
Publicado: (2022)

Unraveling Autonomic Dysfunction in GBA‐Related Parkinson's Disease
por: Devigili, Grazia, et al.
Publicado: (2023)

GBA1 variants in Brazilian Gaucher disease patients
por: Basgalupp, Suelen Porto, et al.
Publicado: (2023)

Parthanatos Mediates AIMP2 Activated Age Dependent Dopaminergic Neuronal Loss
por: Lee, Yunjong, et al.
Publicado: (2013)

Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model
por: Yang, Shi Yu, et al.
Publicado: (2022)

Structure–Activity Studies of N‐Butyl‐1‐deoxynojirimycin (NB‐DNJ) Analogues: Discovery of Potent and Selective Aminocyclopentitol Inhibitors of GBA1 and GBA2
por: Gu, Xingxian, et al.
Publicado: (2017)

PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency
por: Pirooznia, Sheila K., et al.
Publicado: (2020)

GBA server: EST-based digital gene expression profiling
por: Wu, Xin, et al.
Publicado: (2005)

Evolution and clustering of prodromal parkinsonian features in GBA1 carriers
por: Mullin, Stephen, et al.
Publicado: (2019)

Experience in Genetic Counseling for GBA1 Variants in Parkinson's Disease
por: den Heijer, Jonas M., et al.
Publicado: (2020)

The Uncovered Function of the Drosophila GBA1a-Encoded Protein
por: Cabasso, Or, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aed7rrdfkvi1fb4uf39sguu3cn